Foghorn Therapeutics (FHTX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Oncologysrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
HIGH DILUTION RISKDilution score: 51/100 (HIGH), 7.4 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 7.27% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%
- Sector Update: Healthcare Stocks Fall Late Afternoon
- Foghorn Stock Sinks as Lilly Scraps Cancer Deal, Forcing 40% Layoffs
- Top Midday Decliners
- Lilly, Foghorn part ways; Wave’s FDA-approved plans
- Foghorn Therapeutics Halts FHD-909 Development After Phase 1 Clinical Data Review
- FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug?
- Foghorn Therapeutics Provides Update on FHD-909 and Strategic Priorities
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Foghorn Therapeutics.
Full FHTX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.